Neurturin promotes tumor cell motility and angiogenesis in colorectal cancer

Wang, Shuyun; Nie, Limin; Song, Yanxing; Zhang, Fang; Chen, Xiaozheng; Shi, Wenjing; Yang, Zijiang; Sun, Yuping; Dang, Qi; Gao, Aiqin

doi:10.1016/j.yexcr.2022.113049

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, PTPRR exhibits a dual function. Suppression of PTPRR expression in rectal cancer triggers the Ras/ERK/c-Fos signaling pathway, thereby facilitating the development of rectal carcinogenesis 34 .In ovarian cancer, PTPRR functions as a suppressor of tumors by dephosphorylating and rendering β-conjugated proteins inactive 35 , suggesting a potentially protective role.NRTN is a ligand of the neurotrophic factor family, and recent studies have shown that NRTN is associated with rectal, pancreatic, and hepatocellular cancer progression [36][37][38] .IGF-1 is a growth hormone target gene that binds to and activates the receptor tyrosine kinase IGF1 receptor (IGF1R) 39 . Multiple studies have demonstrated its association with resistance to anticancer drugs and highlighted the potential bene ts of targeting IGF1 in anticancer therapy 40,41 .…”

Section: Discussionmentioning

confidence: 99%

Predicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes

Cheng,

Li,

Zhou

et al. 2024

Preprint

View full text Add to dashboard Cite

The mitogen-activated protein kinase (MAPK) pathway plays a critical role in tumor development and immunotherapy. Nevertheless, additional research is necessary to comprehend the relationship between the MAPK pathway and the prognosis of bladder cancer (BLCA), as well as its influence on the tumor immune microenvironment.To create prognostic models, we screened ten genes associated with the MAPK pathway using COX and least absolute shrinkage and selection operator (LASSO) regression analysis. These models were validated in the Genomic Data Commons (GEO) cohort and further examined for immune infiltration, somatic mutation, and drug sensitivity characteristics. Finally, the findings were validated using The Human Protein Atlas (HPA) database and through Quantitative Real-time PCR (qRT-PCR).Patients were classified into high-risk and low-risk groups based on the prognosis-related genes of the MAPK pathway. The high-risk group had poorer overall survival than the low-risk group and showed increased immune infiltration compared to the low-risk group. Additionally, the nomograms built using the risk scores and clinical factors exhibited high accuracy in predicting the survival of BLCA patients.The prognostic profiling of MAPK pathway-associated genes represents a potent clinical prediction tool, serving as the foundation for precise clinical treatment of bladder cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes

Cheng,

Li,

Zhou

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…These Neurotrophins exert their effects by binding to their receptor Trk, which belongs to the growth factor receptor (GFR) superfamily and possesses tyrosine kinase activity. In PDAC, CRC, the expression of these neurotrophic factors, including NGF and GFL neurotrophic factors, is upregulated [ 73 , 74 ]. They can induce the spread of cancer cells around nerves by stimulating the GFRα3/RET receptor or promote neural invasion through activation of the RET-Ras-MAPK pathway, thereby facilitating PDAC metastasis and correlating with a poor prognosis [ 75 , 76 ].…”

Section: Various Patterns Of the Pns-mediated Regulation On Gi Tumori...mentioning

confidence: 99%

The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention

Lyu,

Xie,

Chen

et al. 2023

Oncogene

View full text Add to dashboard Cite

Gastrointestinal (GI) cancer is a formidable malignancy with significant morbidity and mortality rates. Recent studies have shed light on the complex interplay between the nervous system and the GI system, influencing various aspects of GI tumorigenesis, such as the malignance of cancer cells, the conformation of tumor microenvironment (TME), and the resistance to chemotherapies. The discussion in this review first focused on exploring the intricate details of the biological function of the nervous system in the development of the GI tract and the progression of tumors within it. Meanwhile, the cancer cell-originated feedback regulation on the nervous system is revealed to play a crucial role in the growth and development of nerve cells within tumor tissues. This interaction is vital for understanding the complex relationship between the nervous system and GI oncogenesis. Additionally, the study identified various components within the TME that possess a significant influence on the occurrence and progression of GI cancer, including microbiota, immune cells, and fibroblasts. Moreover, we highlighted the transformation relationship between non-neuronal cells and neuronal cells during GI cancer progression, inspiring the development of strategies for nervous system-guided anti-tumor drugs. By further elucidating the deep mechanism of various neuroregulatory signals and neuronal intervention, we underlined the potential of these targeted drugs translating into effective therapies for GI cancer treatment. In summary, this review provides an overview of the mechanisms of neuromodulation and explores potential therapeutic opportunities, providing insights into the understanding and management of GI cancers.

show abstract

“…Neurturin belongs to the family of neurotrophic factors of glial origin. As an endogenous trophic factor, it significantly increases dopamine activity in the midbrain, improves neuronal survival, and protects the integrity of neurons from neurotoxic damage, thus potentially inhibiting the progression of PD [ 65 ]. CERE-120 is an experimental drug comprising an AAV combined with the neurturin gene.…”

Section: Viruses As Drug Delivery Systems In Selected Central Nervous...mentioning

confidence: 99%

Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases

Nowak,

Madej,

Secemska

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Central nervous system (CNS) diseases are currently a major challenge in medicine. One reason is the presence of the blood–brain barrier, which is a significant limitation for currently used medicinal substances that are characterized by a high molecular weight and a short half-life. Despite the application of nanotechnology, there is still the problem of targeting and the occurrence of systemic toxicity. Viral vectors and virus-like particles (VLPs) may provide a promising solution to these challenges. Their small size, biocompatibility, ability to carry medicinal substances, and specific targeting of neural cells make them useful in research when formulating a new generation of biological carriers. Additionally, the possibility of genetic modification has the potential for gene therapy. Among the most promising viral vectors are adeno-associated viruses, adenoviruses, and retroviruses. This is due to their natural tropism to neural cells, as well as the possibility of genetic and surface modification. Moreover, VLPs that are devoid of infectious genetic material in favor of increasing capacity are also leading the way for research on new drug delivery systems. The aim of this study is to review the most recent reports on the use of viral vectors and VLPs in the treatment of selected CNS diseases.

show abstract

Neurturin promotes tumor cell motility and angiogenesis in colorectal cancer

Cited by 8 publications

References 28 publications

Predicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes

Predicting Bladder Cancer Survival with High Accuracy: Insights from MAPK Pathway-related Genes

The nerve cells in gastrointestinal cancers: from molecular mechanisms to clinical intervention

Virus-Based Biological Systems as Next-Generation Carriers for the Therapy of Central Nervous System Diseases

Contact Info

Product

Resources

About